Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (DE:1JK)
FRANKFURT:1JK
RESEARCH TOOLSreports
Apellis Pharmaceuticals (1JK) Stock Price & Analysis
0 Followers
1JK Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€19.00 - €87.50
Previous Close€36.25
Volume0.00
Average Volume (3M)218.00
Market Cap
€4.53B
Enterprise Value€4.33B
Total Cash (Recent Filing)$325.90M
Total Debt (Recent Filing)$109.14M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Aug 05, 2024EPS Estimate
-€0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding121,365,555
10 Day Avg. Volume14
30 Day Avg. Volume218
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)18.48
Price to Sales (P/S)25.36
Price to Cash Flow (P/CF)-9.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.35
Enterprise Value/Gross Profit11.11
Enterprise Value/Ebitda-11.23
Forecast
1Y Price Target
€71.80Price Target Upside98.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Apellis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSyfovre revenues exceeded expectations, with a significant quarterly increase in paid vials and continuing new site growth.
Market LeadershipMarket share of treated GA patients stood at ~85% at the end of the quarter, reflecting clear market leadership for Syfovre.
Market PenetrationOver 2,000 sites are now using Syfovre, and more centers are being added each week, showing expanding market penetration.
Bears Say
Competitive PositionThe safety profiles for the two competitor drugs for geographic atrophy appear differentiated, with Izervay having the early advantage over Syfovre.
Drug SafetyFor APLS' Syfovre, there were 73 additional serious adverse events reported, including 10 additional cases of retinal vasculitis and 2 deaths.
Market PerceptionAnalyst checks indicate Street's combined ~$5B estimate for Syfovre and Izervay are likely too high.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
43.13% Other Institutional Investors
56.87% Public Companies and
Individual Investors
1JK FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was €19.00 and its highest was €87.50 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is Aug 05, 2024 which is in 69 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on May 07, 2024. The company reported -€0.497 earnings per share for the quarter, missing the consensus estimate of -€0.439 by -€0.058.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -€0.26.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Currently, no data Available
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of -€0.497 in its last earnings report, missing expectations of -€0.439. Following the earnings report the stock price went down -7.914%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Among the largest hedge funds holding Apellis Pharmaceuticals Inc’s share is Iron Triangle Partners LP. It holds Apellis Pharmaceuticals Inc’s shares valued at 32M.
---
Apellis Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€71.80 (98.09% Upside)
€71.80 (98.09% Upside)
Blogger Sentiment
Bullish
DE:1JK Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.08%
12-Months-Change
Fundamentals
Return on Equity
-122.94%
Trailing 12-Months
Asset Growth
-15.01%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
---
1JK Company Deck
---
1JK Earnings Call
Q1 2024
0:00 / 0:00
---
1JK Stock 12 Month Forecast
Average Price Target
€71.80
▲(98.09% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Ultragenyx Pharmaceutical
―
Karyopharm Therapeutics
―
Best Analysts Covering 1JK
1 Year
1 Year Success Rate
17/29 ratings generated profit
1 Year Average Return
+15.01%
reiterated a buy rating 4 months ago
Copying Justin Kim's trades and holding each position for 1 Year would result in 58.62% of your transactions generating a profit, with an average return of +15.01% per trade.
---